晚期诊断使患有Psoriatic关节炎(PsA)的人很难获得良好的结果,异质性临床疾病表达,在许多情况下,未能充分抑制炎症性疾病的特征。单中心研究无疑有助于我们对疾病发病机理的理解,但是为了充分解决未满足需求的主要领域,多伙伴,现在需要合作研究方案。HIPPOCRATES是5年,创新药物倡议(IMI)计划,其中包括17个在PsA研究方面经验丰富的欧洲学术中心,5个制药行业合作伙伴,3个中小型行业合作伙伴和2个患者代表组织。在这次审查中,概述了HIPPOCRATES将开展的雄心勃勃的工作方案,并确定了共同的方法和挑战。预计,完成时,结果最终将改变诊断方法,管理和治疗PsA,从而获得更好的短期和长期结果。
改善Psoriatic关节炎的结果Psoriatic关节炎(PsA)是关节炎的一种形式,在大约30%的患有皮肤疾病的人中发现,牛皮癣。经常使人衰弱和进步,对于患有PsA的人来说,很难通过晚期诊断获得良好的结果,疾病的临床特征,在许多情况下,未能充分控制炎症的特征。来自各个中心的研究无疑有助于我们理解为什么人们会发展PsA,但要充分解决未满足需求的主要领域,多中心,现在需要合作研究方案。HIPPOCRATES是5年,创新药物倡议(IMI)计划,其中包括17个在PsA研究方面经验丰富的欧洲学术中心,5个制药行业合作伙伴,3个中小型行业合作伙伴和2个患者代表组织(见附录)。在这次审查中,概述了HIPPOCRATES将开展的雄心勃勃的工作方案,并确定了共同的方法和挑战。强调了患者研究伙伴参与HIPPOCRATES工作的所有阶段。预计,完成时,结果最终将改变诊断方法,管理和治疗PsA,从而改善短期和长期结果。
Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required.
HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations. In this review, the ambitious programme of work to be undertaken by
HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for better short-term and long-term outcomes.
Improving outcomes in Psoriatic Arthritis Psoriatic Arthritis (PsA) is a form of arthritis which is found in approximately 30% of people who have the skin condition, Psoriasis. Frequently debilitating and progressive, achieving a good outcome for a person with PsA is made difficult by late diagnosis, disease clinical features and in many cases, failure to adequately control features of inflammation. Research studies from individual centres have certainly contributed to our understanding of why people develop PsA but to adequately address the major areas of unmet need, multi-centre, collaborative research programmes are now required.
HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient representative organisations (see appendix). In this review, the ambitious programme of work to be undertaken by
HIPPOCRATES is outlined and common approaches and challenges are identified. The participation of patient research partners in all stages of the work of
HIPPOCRATES is highlighted. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for improvements in short-term and long-term outcomes.